Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need
ResearchMoz presents this most up-to-date research on Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need. The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Gastrointestinal Therapeutics in Asia-Pacific Markets.
Albany, NY -- (SBWire) -- 01/28/2014 --Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.
View Full Report With Complete TOC at http://www.researchmoz.us/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need-report.html
Disease overview and treatment usage patterns
Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019
Major marketed products for the indications types covered
In-depth pipeline analysis for IBS, UC and CD
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements in the gastrointestinal therapeutics market
Browse All Reports in Pharmaceutical at http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Reasons to Buy
The report will enhance your decision-making capability by allowing you to:
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Related Reports -
Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.
View Full Report - http://www.researchmoz.us/gastrointestinal-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-counter-declines-from-patent-expiries-report.html
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.
View Full Report - http://www.researchmoz.us/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-report.html
Parkinsons Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management
Parkinson’s Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management”. The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012–2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan. Although a few market entrants are anticipated to enter the market over the forecast period, they are not expected to offset the impact of generic erosion.
View Full Report - http://www.researchmoz.us/parkinsons-disease-therapeutics-market-to-2019-pipeline-shows-shift-towards-long-term-disease-management-report.html
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://pramoddige91.wordpress.com/
Media Relations Contact
View this press release online at: http://rwire.com/448351